The broader applicability of TRPS1 across breast cancer subtypes makes it a more robust marker in both routine and challenging cases, particularly in poorly differentiated tumors or TNBC, where SOX10 alone may not provide sufficient diagnostic clarity. This evidence concerns the gene SOX10 and breast cancer.